Irinotecan in Cervical Cancer

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 94-98

  Kavanagh, John S ^a   Verschraegen, Claire F ^a   Kudelka, Andrzej P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALTRETAMINE; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOLACTOL; MITOMYCIN; PACLITAXEL; RECOMBINANT TUMOR NECROSIS FACTOR; VINBLASTINE; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VOMITING;

EID: 0031795671     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Devesa SS, Silverman DT, Young JL, et al: Cancer incidence and mortality trends among whites in the United States: 1947-1984. J Natl Cancer Inst 79:701-770, 1987
2. Landis SH, Murray T, Bolden S: Cancer statistics, 1998 CA Cancel J Clin 48(1):10-11, 1998.
3. Parkin DM, Muir CS, Whelan SL, et al: (eds) Cancer Incidence in Five Continents, vol VI. Lyon. International Agency for Research on Cancer, 1992.
4. Carlson V, Delclos L, Fletcher GH, et al Distant metastasis in squamous cell carcinoma of the uterine cervix. Radiology 88:961-966, 1967
5. Yang I, Liu LF, Li JJ, et al: The roles of DNA topoisomerase in SV 40 DNA replication. UCLA Sympos Mol Cell Biol 47:315-326, 1986.
6. Liu LF, Wang JC: Supercoiling of DNA template during transcription. Proc Natl Acad Sci USA 84:7024-7027, 1987.
7. Wang JC: DNA topoisomerases: Why so many J Biol Chem 6:6659-6662, 1991.
8. Wall ME, Wam MC, Cooke ET, et al: Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966.
9. Sasaki Y, Morita M, Miya T, et al: Pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Proc Am Soc Clin Oncol 11:11, 1992.
10. Chabot G, De Forni M, Abigerges D, et al: Clinical trials and pharmacology studies of CPT-11 and its active metabolite SN-38 in France: Preliminary pharmacokinetic-pharmacodynamic relationships, in Potmesil M, Pinedo H (eds): Camptothecins: New Anticancer Agents, pp 83-92 Boca Raton, Florida, CRC Press, 1995.
11. Chabot G, Gouyette A, Bissery M: Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan and active metabolite SN-38 in mice Proc Am Assoc Cancer Res 35:A2576, 1994.
12. Wang Y, et al: Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Jpn J Cancer Chemother 14(5):1264, 1987.
13. Masumoto N, Nakano S, Esaki T, et al: Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res 15(2):405-409, 1995.
14. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous cell carcinoma cells. Int J Cancer 62:70-75, 1995.
15. Tamura K, Takada M, Masuda N, et al: Radiosensitization effect of CPT-11 against human lung tumor xenografts. Proc Am Assoc Cancer Res 36:605, 1995
16. Watanabe A, Nishiwaki K, Hasegawa Y, et al: Effects of Taxotere (docetaxel) and innotecan (CPT-11) combined with radiation on lung cancer cell lines. Proc Am Soc Clin Oncol 14:494, 1995.
17. Mon H, Sawairi M, Itoh N, et al: Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines. Anticancer Drugs 2:469-474, 1991.
18. Sawaiiri M, Itoh N, Hanabayashi H, et al: Caffeine enhancement of the effects of cisplatin and CPT-11 on gynecologic tumor cell lines (abst 1610). Proc Int Cong Chemother 1991.
19. Verschraegen CF, Levy T, Kudelka AP, et al: Phase II study of innotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J Clin Oncol 15:625-631, 1997.
20. Look KY, Blessing JA, Levenback C, et al: A phase II trial of CPT-11 in chemotherapynaive patients with recurrent squamous carcinoma of the cervix: A Gynecologic Oncology Group. In: Proceedings of the 29th Annual Meeting of the Society of Gynecologic Oncologists. Abstract No. 134. February 7-11, 1998, Orlando, Florida.
21. Rebattu P, Fumoleau P, Roche H, et al: Phase II trial of CPT-11 in advanced cervical carcinoma. Proc Am Soc Clin Oncol 14:A737, 1995
22. Irvin WP, Price FV, Bailey H, et al: A phase II study of irnotecan (CPT-11 ) in patients with advanced squamous cell carcinoma of the cervix. Cancer 82(2):328-333, 1998.
23. Chevallier B, Lhomme C, Dieras V. et al: Phase II trial of CPT-11 in advanced cervical carcinoma. Proc EORTC Early Drug Devel Ming, June 21-24, 1995, Cortu, Greece, page 92.
24. Society of Japanese Pharmacopoeia: Summary Basis Approval No. 1: Irinotecan Hydrochloride (Campto Injection) (Topotecin Injection). pp 23-28. Yakuji Nippo, Ltd, 1996.
25. Takeuchi S, Noda K, Yakuhiji M, et al: Late phase II study of CPT-11, a topoisomerase-I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:A708, 1992.
26. Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers Jpn J Cancer Chemother 18:1681-1689, 1991
27. Curtin J, Lanciano R, Kudelka AP: Cervical cancer, in Pazdur R, Coia L, Hoskins W, Wagman L (eds): Cancer Management A Multidisciplinary Approach, 2nd ed, pp 149-173. Huntington. New York, PRR, 1998.
28. Petterson F (ed): Annual report on the results of treatment in gynecological cancer. Int J Obstet 36:35, 1991.
29. Lopez A, Kudelka AP, Edwards CL, Kavanagh JJ: Carcinoma of the uterine cervix, in Pazdur R (ed): Medical Oncology: A Comprehensive Review, pp 393-405 Huntington, New York, PRR, 1996.